Abstract 122P
Background
Cribriform (cbf) morphology has been shown in carcinomas from various organs, including prostate and breast, to be associated with worse patient outcomes and unique molecular features. We sought to examine the multimodal data from the landmark Cancer Genome Atlas (TCGA) study to clarify molecular and prognostic factors associated with cbf morphology in colorectal adenocarcinomas.
Methods
We retrospectively analyzed the available TCGA CRC cohort (n=594). Clinicopathological, digital slides, and molecular data were extracted. Cases with insufficient clinical data, no diagnostic slides, or poor slide quality were excluded. TCGA coded data, pathology reports, and digital diagnostic slides were reassessed by one gastrointestinal pathologist and a resident. Cbf morphology was graded using five categories based on prostate cribriform studies: (0) no-cribriform, (1) loose cribriform, (2) small cribriforming glands, (3) diffuse large cribriform, and (4) intraductal carcinoma of the prostate-like. Cases were grouped into cbf 'low' (0-1) and cbf 'high' (2-4) groups, which were correlated with clinicopathological, histological and molecular features. Immune infiltration was characterized by cell type fraction. An adjusted α = 0.05 for statistical significance was used for all tests.
Results
573 CRC cases were included. Cbf 'high' CRCs (159/573) were associated with more left-sided tumors (p=0.049), metastatic diseases (p=0.0001), less MSI-H (p=0.003), and different aneuploidy and fraction genome altered (p=0.003-0.008). Cbf 'high' vs 'low' tumors did not show a significant difference in grading distribution. T and N staging were not associated with cbf morphology. By cell fraction, cbf ‘high’ CRCs showed an immune infiltrate with increased regulatory T cells (p<0.0001) but decreased memory B cells (p=0.046), M2 macrophages (p<0.0001), neutrophils (p=0.018), resting dendritic cells (p=0.046), compared with cbf ‘low’ CRCs. Cbf 'high' tumor morphology was associated with worse overall survival outcomes by log-rank testing (p=0.037).
Conclusions
Cribriform morphology in colorectal adenocarcinoma TCGA cases was associated with poorer outcomes and distinct transcriptomic immune profiling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Q-H. Trinh.
Funding
Fonds de recherche Santé Québec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract